Pavmed INC 8-K filings

PAVmed Inc. announced second quarter 2026 financial results and business updates, highlighting accelerated commercial engagement for Veris Health, new coverage for Lucid Diagnostics' EsoGuard, and positive early results for its medical device portfolio.

PAVmed Inc. stockholders re-elected two directors and approved amendments to the Employee Stock Purchase Plan at the 2026 Annual Meeting.

PAVmed Inc. announced its first quarter 2026 financial results and provided a business update, highlighting progress in its subsidiaries Veris Health and Lucid Diagnostics, alongside advancements in its relaunched medical device portfolio.

PAVmed reported Q4/FY2025 results, strengthened its balance sheet with $45M in new financing, eliminated convertible overhang, and advanced Veris and Lucid programs toward key regulatory and reimbursement milestones.

PAVmed Inc. stockholders approved proposals for stock issuance, director removal, and an increase in the equity incentive plan shares at a special meeting.

PAVmed Inc. announced the closing of $30 million in Series D Convertible Preferred Stock and a $15 million senior secured note, eliminating all previously outstanding convertible securities and strengthening its balance sheet.

PAVmed Inc. announced it has regained compliance with Nasdaq's $1 minimum bid price requirement, avoiding potential delisting.

PAVmed Inc. will implement a 1-for-30 reverse stock split and reduce authorized shares to regain compliance with Nasdaq's minimum bid price requirement, effective January 2, 2026.

PAVmed Inc. stockholders approved a proposal to effect a reverse stock split and reduce authorized common stock at a special meeting on December 5, 2025.

PAVmed Inc. announced third quarter 2025 financial results and significant business advancements for its subsidiaries, Veris Health and Lucid Diagnostics.

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., successfully closed its previously announced underwritten public offering, raising approximately $26.9 million in net proceeds.

PAVmed Inc. reports Q2 2025 financial results, highlighting successful subsidiary financings and strategic advancements for Lucid Diagnostics and Veris Health.

PAVmed Inc. has been granted an additional 180 calendar days by Nasdaq to regain compliance with the minimum $1 bid price requirement, extending the deadline to January 19, 2026.

PAVmed Inc.'s majority-owned subsidiary, Veris Health Inc., has successfully raised approximately $2.5 million through a private placement of common stock and warrants to fund the continued development of its implantable physiological monitor and for general working capital.

PAVmed Inc. announced that its stockholders approved all management-backed proposals, including the re-election of two Class C directors and the amendment of its long-term incentive plan, at the annual meeting held on June 18, 2025.

PAVmed Inc. announced its Q1 2025 financial results, highlighting Lucid Diagnostics' capital raise and Veris Health's progress, while also revealing plans to expand into the biopharma sector.

PAVmed Inc. reports a change in its independent registered public accounting firm from Marcum LLP to CBIZ CPAs following CBIZ's acquisition of Marcum's attest business.

PAVmed Inc. has entered into a sales agreement with Maxim Group LLC for an at-the-market offering of up to $2.88 million of its common stock.

Lucid Diagnostics, a subsidiary of PAVmed Inc., successfully closed a public offering of common stock, raising approximately $16.1 million in net proceeds.

PAVmed reports its 2024 financial results, highlighting Lucid Diagnostics' record test volume and first commercial insurance coverage, and Veris Health's secured financing for its implantable physiological monitor.

Lucid Diagnostics, a subsidiary of PAVmed Inc., successfully closed a common stock offering, raising approximately $14.5 million in net proceeds for working capital and general corporate purposes.

PAVmed Inc. announced the completion of a private placement, raising $2.37 million to support the development of Veris Health's implantable physiological monitor and for general working capital.

PAVmed Inc. announced that it has regained compliance with Nasdaq's continued listing standard, specifically maintaining at least $2.5 million in stockholders' equity.

PAVmed Inc. received a delisting notice from Nasdaq due to its stock price falling below $1 and completed a debt-for-equity swap, issuing Series C Preferred Stock.

PAVmed Inc. exchanged $22.3 million of convertible notes for Series C Convertible Preferred Stock, aiming to improve its financial position and meet Nasdaq listing requirements.

PAVmed Inc. announces stockholder approval for increasing authorized common stock and issuing shares upon conversion of Series C Preferred Stock.

Lucid Diagnostics, a subsidiary of PAVmed, completed a $21.95 million private placement of senior secured convertible notes, using a portion of the proceeds to repay existing debt.

PAVmed Inc. has entered into agreements to exchange existing debt for Series C Convertible Preferred Stock and to sell additional shares of the same preferred stock, aiming to reduce debt and raise capital.

PAVmed reports record quarterly revenue for its Lucid Diagnostics subsidiary's EsoGuard test, completes clinical evidence package for Medicare submission, and makes progress towards Nasdaq listing compliance.

PAVmed Inc. has deconsolidated Lucid Diagnostics from its financial statements and appointed a new director as part of its efforts to regain compliance with Nasdaq listing requirements.